Corundum System Biology has invested in Freya Biosciences to support the development of innovative immunotherapy solutions for women's reproductive health.
Target Information
Corundum System Biology, based in Minato, Tokyo, and led by CEO Hidehiko Otake, has recently made a strategic investment in the biotechnology sector with a focus on women's reproductive health. This investment is part of a larger Series A funding round that has raised a total of USD 38 million for Freya Biosciences, a clinical-stage startup based in Denmark and the United States, under the leadership of CEO Colleen Acosta. Freya Biosciences specializes in immunotherapy related to women's reproductive health, currently developing vaginal microbiome immunotherapy aimed at treating infertility in women with vaginal microbiome imbalances who are undergoing assisted reproductive technologies (ART), including in vitro fertilization (IVF).
Corundum System Biology will also support Freya Biosciences' expansion into the Japanese and South Korean markets, where there is a high demand for IVF services.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The reproductive health biotechnology industry is rapidly evolving, particularly in countries like Japan and South Korea, where advancements in ART are essential to addressing the burgeoning infertility rates. These nations have wi
Similar Deals
Fåhraeus Startup & Growth Fund II (FSG) → Fida Biosystems
2025
コランダム・システム・バイオロジー
invested in
フレイヤ・バイオサイエンス
in 2023
in a Series A deal
Disclosed details
Transaction Size: $38M